Bristol-Myers Squibb Co. looks set to make a mark in treating classical Hodgkin lymphoma: it has announced new data showing positive results for its immune-oncology therapy Opdivo in previously treated HL patients supporting the use of checkpoint inhibitors blood cancers as well as solid tumors.
The CheckMate -205 study evaluates Opdivo in patients with classical Hodgkin lymphoma (HL) and the data revealed by BMS focuses on patients who relapsed or progressed after stem cell transplantation...